Panel Discussion: Myeloma & Lymphoma
نویسندگان
چکیده
Non-Hodgkin’s lymphoma (NHL) is the third most frequent malignant tumour in the head and neck, basocellular carcinoma of the skin and mucosal squamous cell carcinoma being the most frequent. Although nodal enlargement is the most common presentation in the head and neck, NHL may occur in extranodal locations. Two distinct extranodal sites are recognised: extranodal lymphatic locations or involvement of the ring of Waldeyer, and extranodal extralymphatic locations. Neck extranodal NHL does not show pathognomonic imaging signs. However, if more than one extranodal mass is detected, if the mass appears huge without necrosis or ulceration, or when associated with large, non-necrotic adenopathies, the diagnosis of NHL can be suggested. The possibility of NHL should be kept open in any infiltrating soft tissue mass in the head and neck region. While fine needle aspiration is often helpful to reach a diagnosis of squamous cell carcinoma, formal biopsy is usually required to diagnose lymphoma. Head and neck Hodgkin’s lymphoma is less common than NHL. Furthermore, extranodal involvement only rarely occurs in Hodgkin’s lymphoma.
منابع مشابه
Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus pr...
متن کاملThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consistin...
متن کاملOptimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine ...
متن کاملCharacteristics of Potential Protein Biomarkers Extracted with 10% TCA from Blood Serum of Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients
Blood serum has been extensively explored as a source of the bio-markers [1, 2]. For concentration of minor protein(s) and depletion of abundant blood serum proteins a 2,2,2-trichloroacetic acid (TCA) precipitation procedure is frequently applied [3]. However, a significant amount of proteins may be present in the TCA extracts, and these proteins are often not studied.Recently, we have sh...
متن کاملHodgkin’s Lymphoma Occurring Secondary to Autologous Stem Cell Transplantation in Plasma Cell Leukemia; A Case Report
Survival of patients with multiple myeloma has improved substantially because of availability of new therapies including autotransplants, immunomodulating drugs and proteasome-inhibitors. Second primary cancers have emerged as an important determinant of morbidity and mortality among cancer survivors. Even though there is an increased risk of new cancers of the lymphoreticular and haematopoetic...
متن کامل